News

James joined Auron in February 2022 as Director of Chemistry. Prior to joining Auron, James worked in the global discovery chemistry group within Novartis Institutes for BioMedical Research (NIBR). James has supported multiple disease areas throughout his tenure at Novartis, most recently supporting the Neuroscience disease area where he was project leader for a program…

Dr. DeBartolo joined Auron Therapeutics in June 2021 as Associate Director, Computational Biology. Most recently he was Senior Principal Scientist of Bioinformatics at BioMedicine Design Pfizer in Cambridge MA where he built database-linked applications and visual analysis tools for NGS platforms, including single-cell RNA-seq and DNA Ig-Seq. A big part of this work involved designing…

Betty joined Auron Therapeutics in January 2021.  She is a data-driven and motivated scientist with 15+ years of experience building and leading biochemistry capabilities.  Betty’s interest and expertise include advancing small molecules from various hit finding approaches (including DNA-encoded library screening and machine learning) to IND filing and developing innovative assays to interrogate new modalities…

Laura Antipov is a self-proclaimed “start-up junkie” with a passion for taking big ideas and translating them into clear, actionable plans. She has been in the biotech industry for 10 years, at three different early stage start-ups, always playing the same role: a “Jack-of-all-trades” problem solver. Laura joined Auron in January 2019; prior to that,…

Andrea is thrilled to join Auron as chief people officer.   She has a demonstrated history of working in the biotechnology and healthcare industries, where she is skilled in biotech recruiting, professional development, executive coaching, strategic organizational development, planning and management.  She also serves as chief people officer at AI Proteins.  Andrea was the chief…

Tom Graeber, Ph.D. is the Chief Data Officer at Auron Therapeutics. Tom has an established academic career in the systems biology of cancer. His research integrates multi-omic profiling, experimentation, and computational biology. His work in integrated signaling and metabolic networks has repeatedly pointed to the importance of negative and positive feedback loops in cancer phenotypes,…

Before joining Auron, David was the Vice President of Chemistry at Foghorn Therapeutics, where he led and built the chemistry function, including a protein degrader platform. David played a key role in the early evolution of the company, through the IPO and contributed to bringing in partnerships with Merck and Lilly Loxo. He was a…

Kate Yen, PhD, is the Founder and CEO of Auron Therapeutics. Prior to founding Auron, she was a Director at Agios Pharmaceuticals, where she led the IDH translational research team that supported the preclinical and clinical development and approval of two IDH mutant inhibitors, IDHIFA®  and TIBSOVO. She led the proof of concept studies that…